Francesca Masci
About Francesca Masci
Francesca Masci is a Senior Scientist based in Oxford, United Kingdom, with expertise in engineering T cell receptors for cancer treatment. She has a background in Medical Biotechnology and Oncology, holding degrees from Università 'Magna Graecia' di Catanzaro and the University of Southampton.
Work at Adaptimmune
Francesca Masci has been employed as a Senior Scientist at Adaptimmune since 2017. In this role, she focuses on advancing T cell receptor therapies aimed at improving the specificity and efficacy of T cells in targeting cancer cells. Her work involves the engineering of T cell receptors to enhance their ability to recognize and bind to cancer cells, which is crucial for the development of effective cancer treatments.
Education and Expertise
Francesca Masci holds a Master's degree in Medical Biotechnology from Università 'Magna Graecia' di Catanzaro, where she studied from 2005 to 2010. She furthered her education at the University of Southampton, completing a Visitor PhD in Oncology and Cancer Biology from 2013 to 2015. This educational background provides her with a strong foundation in both biotechnology and oncology, contributing to her expertise in cancer research.
Background
Francesca Masci began her professional career as a Scientist in 2015, where she has accumulated nine years of experience in the field. Her work primarily involves the development of T cell receptor therapies, focusing on the screening of donor T cells to assess their ability to recognize specific peptide antigens. This background has equipped her with the skills necessary to contribute significantly to cancer therapy development.
Research Focus
Francesca Masci's research is centered on engineering T cell receptors to improve their specificity and efficacy in targeting cancer cells. She develops therapies that enhance T cell recognition and binding to cancer cells, which is essential for effective immunotherapy. Her work includes screening donor T cells for their ability to recognize specific peptide antigens, a critical step in the therapy development process.